AEON Biopharma, Inc.
AEON · AMEX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $14,181 | $33,046 | $34,754 | $25,728 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $13,643 | $19,790 | $13,675 | $11,153 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$100,809 | $295,250 | $0 | $28,966 |
| Operating Expenses | -$72,985 | $348,086 | $48,429 | $65,847 |
| Operating Income | $72,985 | -$348,086 | -$48,429 | -$65,847 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$30,980 | -$36,546 | -$4,127 | $10,210 |
| Pre-Tax Income | $42,005 | -$384,632 | -$52,556 | -$55,637 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | $42,005 | -$384,632 | -$52,556 | -$55,637 |
| % Margin | – | – | – | – |
| EPS | 77.74 | -4.99 | -27.25 | -31.73 |
| % Growth | 1,657.9% | 81.7% | 14.1% | – |
| EPS Diluted | 72.93 | -4.99 | -27.25 | -31.73 |
| Weighted Avg Shares Out | 575 | 77,072 | 1,928 | 1,753 |
| Weighted Avg Shares Out Dil | 576 | 77,073 | 1,928 | 1,754 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $97 | $99 | $68 | $3 |
| EBITDA | -$27,727 | -$52,737 | -$48,361 | -$36,878 |
| % Margin | – | – | – | – |